echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > New Coronary Pneumonia Diagnosis and Treatment Plan Revised!

    New Coronary Pneumonia Diagnosis and Treatment Plan Revised!

    • Last Update: 2022-04-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    In order to further improve the medical treatment of new coronary pneumonia and effectively improve the level of standardized and homogenized diagnosis and treatment, the National Health Commission and the State Administration of Traditional Chinese Medicine organized experts to conduct a review of the "New Coronary Virus Pneumonia Diagnosis and Treatment Plan (Trial 8th Edition > Revised Edition)" It has been revised to form the "New Coronary Virus Pneumonia Diagnosis and Treatment Plan (Ninth Edition for Trial Implementation)", which has been issued for reference and implementation in various places
    .
    The new version of the diagnosis and treatment plan is formed on the basis of careful study of the transmission characteristics and case characteristics of mutant strains such as Delta and Omicron, and in-depth analysis of relevant research results
    .
    The key revisions are as follows: First, optimize the case finding and reporting procedures
    .
    On the basis of nucleic acid detection, antigen detection is added as a supplement to further improve the ability of early detection of cases
    .
    At the same time, the efficiency of diagnosing or excluding suspected cases is improved, and the suspected cases or those with positive antigen test results are required to undergo nucleic acid testing immediately or closed-loop transfer to a qualified higher-level medical institution for nucleic acid testing
    .
    Those with a positive nucleic acid test result will be quarantined in a centralized manner or sent to a designated hospital for treatment, and will be reported directly online in accordance with regulations
    .
    The second is to implement classified treatment of cases
    .
    According to the opinions reflected in various places, such as "patients with Omicron variant strains are mainly asymptomatic infections and mild cases, most of them do not require excessive treatment, and all admission to designated hospitals will take up a lot of medical resources" and other opinions, the classification of cases has been further improved.
    Admission measures: 1.
    Mild cases are subject to centralized isolation management, and relevant centralized isolation places cannot isolate inbound personnel, close contacts and other groups at the same time
    .
    During the isolation management period, symptomatic treatment and condition monitoring should be done.
    If the condition worsens, it should be transferred to a designated hospital for treatment
    .
    2.
    Ordinary, severe, critical cases and cases with severe high-risk factors should be centrally treated in designated hospitals.
    Severe and critical cases should be admitted to ICU for treatment as soon as possible, and patients with high-risk factors and prone to severe disease should also be admitted to ICU for treatment.

    .
    The third is to further standardize antiviral treatment
    .
    Two specific anti-new coronavirus drugs approved by the State Food and Drug Administration were written into the diagnosis and treatment plan, namely: PF-07321332/ritonavir tablet (Paxlovid) and domestic monoclonal antibody (ambavirumab/romisevir) monoclonal antibody injection)
    .
    Fourth, the content of TCM treatment has been revised and improved
    .
    Combined with the clinical treatment experience in various places, the application of non-drug therapy of traditional Chinese medicine was strengthened, and the content of acupuncture and moxibustion treatment was added; combined with the characteristics of children, the content of traditional Chinese medicine for children was added
    .
    The fifth is to adjust the management of release from isolation and discharge standards, as well as the management of release from isolation and precautions after discharge
    .
    Relevant domestic studies have shown that when the nucleic acid Ct value of infected persons in the recovery period is greater than or equal to 35, the virus cannot be isolated from the samples, and close contacts have not been found to be infected
    .
    Accordingly, the new version of the diagnosis and treatment plan will change the "two consecutive negative nucleic acid tests of respiratory specimens (sampling time interval of at least 24 hours)" in the criteria for release from isolation and discharge to "two consecutive nucleic acid tests for the novel coronavirus N gene and ORF gene Ct" All values ​​≥ 35 (fluorescence quantitative PCR method, the cutoff value is 40, and the sampling time is at least 24 hours apart), or two consecutive new coronavirus nucleic acid tests are negative (fluorescence quantitative PCR method, the cutoff value is less than 35, and the sampling time is at least 24 hours apart) hours)"
    .
    "Continue 14-day isolation management and health status monitoring after discharge" is revised to "Release isolation management or continue to conduct 7-day home health monitoring after discharge"
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.